PRECLINICALDEVELOPMENT STRATEGY

PRECLINICALDEVELOPMENT STRATEGY

Situation: A mid-sized US biotech historically focused on the infectious disease space experienced a late-stage failure. In consequence, the management changed the company’s strategic focus by in-licensing an early-stage asset targeting an orphan autoimmune disease. The firm is looking to complement the ongoing clinical studies with meaningful preclinical insights into the mode of action.

Approach: SCITARIS helped building various target and mode of action hypotheses for the molecule based on extensive literature research and key opinion leader interviews. Proposals for relevant experiments to test each of these hypotheses were designed and prioritized with the scientific teams, as well as suitable CROs and academic institutions identified to conduct these studies.

Outcome: The company initiated studies SCITARIS recommended and has generated first signals to be presented to investors and at upcoming scientific conferences.